English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech Healthcare & Pharm
德视佳收购London Vision Clinic Partners Limited 100%已发行股本
Jan 28, 2022 15:57 HKT
德視佳收購London Vision Clinic Partners Limited 100%已發行股本
Jan 28, 2022 15:56 HKT
EuroEyes Acquires 100% Issued Shares in London Vision Clinic Partners Limited
Jan 28, 2022 15:55 HKT
金活醫藥授出155.6萬股獎勵股份 推動公司長遠穩定發展
Jan 28, 2022 08:30 HKT
Labnovation's COVID-19 ART Test Kit, Imported by Clearbridge, one of two COVID-19 ART Test Kits approved by Philippines FDA for Self-Testing
Jan 26, 2022 20:45 HKT
HMI Group Strengthens Specialist Offering, Acquires Majority Stake in Eagle Eye Centre
Jan 24, 2022 11:00 HKT
Avance Clinical在2022年生物技术展上宣布为美国扩张进行重大私募股权投资
Jan 19, 2022 07:00 HKT
Avance Clinical在2022年生物技術展上宣佈為美國擴張進行重大私募股權投資
Jan 19, 2022 07:00 HKT
아방스 클리니컬 바이오테크 쇼케이스 2022에서 미국에서의 확장을 위한 대규모적인 PE 투자를 발표
Jan 19, 2022 07:00 HKT
Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022
Jan 18, 2022 13:00 HKT
医思健康管理层增持公司股份 对集团发展前景充满信心
Jan 17, 2022 20:20 HKT
醫思健康管理層增持公司股份 對集團發展前景充滿信心
Jan 17, 2022 20:19 HKT
Senior Management Increases Shareholdings in EC Healthcare With Strong Confidence in the Group's Future Development
Jan 17, 2022 20:18 HKT
Arcensus has appointed Prof. Dr. Arndt Rolfs as New CEO
Jan 12, 2022 15:00 HKT
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
Jan 12, 2022 10:26 HKT
中国抗体荣获“第六届金港股”评选中“最佳中小市值公司”、“最佳CEO”奖项及“2021新浪财经金麒麟最佳港美股上市公司”评选中“最具成长潜力上市公司”奖项
Jan 11, 2022 16:57 HKT
中國抗體榮獲「第六屆金港股」評選中「最佳中小市值公司」、「最佳CEO」獎項及「2021新浪財經金麒麟最佳港美股上市公司」評選中「最具成長潛力上市公司」獎項
Jan 11, 2022 16:56 HKT
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies"
Jan 11, 2022 16:55 HKT
Clinical Evaluation of LeSoleil Against COVID-19
Jan 11, 2022 12:00 HKT
艾美mRNA新冠疫苗(LVRNA009)I期臨床試驗結果大獲業界好評:安全耐受性良好
Jan 10, 2022 09:36 HKT
Next >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: